BNP Paribas Financial Markets’s Evogene EVGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.24K Sell
2,830
-6,294
-69% -$4.36K ﹤0.01% 5577
2026
Q1
$7.03K Sell
9,124
-1,000
-10% -$945 ﹤0.01% 5277
2025
Q4
$11.1K Sell
10,124
-1,107
-10% -$1.29K ﹤0.01% 5140
2025
Q3
$12.8K Sell
11,231
-2,888
-20% -$3.66K ﹤0.01% 4973
2025
Q2
$18.1K Buy
14,119
+1,300
+10% +$1.59K ﹤0.01% 4649
2025
Q1
$16.3K Hold
12,819
﹤0.01% 4589
2024
Q4
$24K Buy
12,819
+619
+5% +$1.22K ﹤0.01% 4685
2024
Q3
$37.5K Buy
12,200
+2,161
+22% +$9.32K ﹤0.01% 3675
2024
Q2
$65.3K Buy
10,039
+899
+10% +$6.28K ﹤0.01% 3393
2024
Q1
$68.5K Buy
9,140
+2,150
+31% +$17.9K ﹤0.01% 3524
2023
Q4
$58.7K Buy
6,990
+400
+6% +$2.52K ﹤0.01% 3529
2023
Q3
$38.6K Buy
6,590
+3,920
+147% +$34.3K ﹤0.01% 3502
2023
Q2
$28.6K Buy
2,670
+1,939
+265% +$13.1K ﹤0.01% 3559
2023
Q1
$4.6K Buy
731
+441
+152% +$3.28K ﹤0.01% 3589
2022
Q4
$2.03K Buy
+290
New +$2.04K ﹤0.01% 3740
2022
Q3
Sell
-10
Closed -$74 4810
2022
Q2
$74 Buy
+10
New +$98 ﹤0.01% 4028

Other funds holding EVGN

BNP Paribas Financial Markets's EVGN Position: Q2 2026 in Review

BNP Paribas Financial Markets reduced its Evogene (EVGN) stake by 69% in Q2 2026, selling an estimated $4.36K and leaving 2,830 shares worth $1.24K. The position accounts for ﹤0.01% of the portfolio, ranked #5577.

BNP Paribas Financial Markets first reported a position in EVGN in Q2 2022 and has held it in 16 quarters since. The position peaked at $68.5K in Q1 2024. 12 funds tracked by Wall St. Rank hold EVGN as of Q2 2026.

  • BNP Paribas Financial Markets held 2,830 shares of Evogene worth $1.24K as of Q2 2026.
  • BNP Paribas Financial Markets sold 6,294 Evogene shares in Q2 2026, an estimated $4.36K.
  • Evogene made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #5577 holding.
  • BNP Paribas Financial Markets first reported a position in Evogene in Q2 2022 and has held it in 16 quarters since.
  • BNP Paribas Financial Markets's Evogene position peaked at $68.5K in Q1 2024.
  • 12 funds tracked by Wall St. Rank held Evogene as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.